Colt Ventures

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. The company's integrated drug-hunting engine is designed to accelerate drug discovery by unlocking targets with great potential and minimizing attrition.

EBY is a membership-based company driving profits with purpose. EBY repositions underwear as a tool for empowerment rather than one of seduction. In fact, 10% of net sales go to the Seven Bar Foundation to empower women out of poverty and into business via microfinance with a small loan, what we call a first break, that can be as little as $80 or as large as $7,000. This loan enables an underprivileged woman to start or grow her business. As she becomes self-sufficient the cycle of poverty is broken. Loans are repaid and passed to another woman, creating a multiplier effect. EBY consistently fuels this loop so that it never ends, creating more first breaks and more bionic women. We’re not about token donations, but rather long-term solutions.

Rumble is an open video management system for publishers and creators. It develops a rights management video platform providing visitors to access content through the internet and offers the opportunity for users to submit text, pictures, video, and other content for posting on the website.

Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. Erasca was founded in 2018 and is headquartered in San Diego, California.

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The company aims to leverage innovative technologies to provide solutions for individuals affected by genetic diseases.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.